DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was validated by the European Medicines Agency (EMA).
Specifically, the MAA is for its investigational product Viaskin Peanut (DBV712). The validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. The EMA’s Committee for Medicinal Products for Human Use (CHMP) will review the application and provide a recommendation to the European Commission (EC) on whether to grant a marketing authorization.
Looking ahead, DBV expects to receive the first set of questions from the EMA roughly 120 days post-validation.
Separately, DBV Tech mentioned that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) back in August 2020 for its Biologics License Application (BLA) for investigational Viaskin Peanut. The company is in the process of engaging FDA to discuss the regulatory path forward.
Previously, the FDA has identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study. The FDA also has indicated that supplementary clinical data would need to be generated to support the modified patch. Additionally, the FDA requested additional Chemistry, Manufacturing and Controls data. Note that the FDA did not raise any safety concerns related to Viaskin Peanut.
Excluding Monday’s move, DBV Tech had vastly underperformed the broad markets with its stock down 87% year to date. In the past 52 weeks, the stock was down closer to 80%.
DBV Technologies stock was last seen up 65% at $2.36, in a 52-week range of $1.35 to $13.49. The consensus price target is $6.25.
The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.